Pharmacoeconomics of etravirine.

Abstract

HIV infection, particularly multidrug-resistant HIV, continues to be a major societal and economic challenge worldwide. Etravirine, a new (US FDA approved in 2008) non-nucleoside reverse transcriptase inhibitor, has been shown to be very effective in treating patients who have failed prior antiretroviral therapy. Clinical studies demonstrated that etravirine in combination with other antiretrovirals achieved superior levels of undetectable plasma HIV RNA and CD4 cell count increases that led to reductions in risk of death and development of AIDS-defining illnesses when compared with placebo. Etravirine was also shown to be generally well tolerated, with favorable CNS and psychiatric tolerability profiles. In addition, etravirine in combination with other antiretrovirals has been shown to improve quality of life and quality-adjusted life expectancy. Economic evaluations showed that the addition of etravirine to a regimen was associated with lower costs per person with an undetectable viral load and lower hospital-related costs compared with placebo.

• Authors: D S Fullerton, Mary Jane Watson, David Anderson, James Witek, Silas C Martin, Joseph M Mrus
• Journal: Expert review of pharmacoeconomics & outcomes research (Expert Rev Pharmacoecon Outcomes Res) Vol. 10 Issue 5 Pg. 485-95 (Oct 2010) ISSN: 1744-8379 [Electronic] England
• PMID: 20950062 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Anti-HIV Agents
• Nitriles
• Pyridazines
• Pyrimidines
• RNA, Viral
• etravirine

Topics

• Anti-HIV Agents (adverse effects, economics, therapeutic use)
• CD4 Lymphocyte Count
• Clinical Trials as Topic
• Economics, Pharmaceutical
• HIV Infections (drug therapy, economics)
• Humans
• Nitriles
• Pyridazines (adverse effects, economics, therapeutic use)
• Pyrimidines
• Quality of Life
• Quality-Adjusted Life Years
• RNA, Viral (blood)